ESMO 2026: UT MD Anderson highlights innovative approaches to monitor, prevent and treat cancer
ABSTRACTS: 3438O, 4244RO, 540RO, 2490P
Researchers at Â鶹ӳ» MD Anderson Cancer Center presented new findings at the European Society for Medical Oncology (ESMO) Congress 2026 showcasing emerging strategies to better monitor treatment responses, to prevent cancer development in high-risk individuals and to improve outcomes with targeted therapies. This research spans multiple disease settings, including lung cancer...
ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer
Patients receiving durvalumab plus olaparib lived almost one year longer than patients treated with chemotherapy alone?
Study...
Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer in Phase 1b trial
Firmonertinib is an experimental therapy from ArriVent BioPharma for patients with EGFR PACC mutations
PACC mutations make up about...
AI tool reveals what attracts immune cells to tumors and what keeps them away
Researchers developed a new artificial intelligence (AI) tool that can help explain where immune cells gather in the body and what guides them there
The AI tool identifies signals linked to attracting or repelling immune cells and could be used across cancer and other diseases
A key finding suggests that mucins, sugar-coated proteins overproduced by many cancers, may form a physical barrier that keeps T cells away from tumors
The tool offers...
